WO2017126700A9 - Inhibitor of activity of vesicular nucleotide transporter - Google Patents

Inhibitor of activity of vesicular nucleotide transporter Download PDF

Info

Publication number
WO2017126700A9
WO2017126700A9 PCT/JP2017/002036 JP2017002036W WO2017126700A9 WO 2017126700 A9 WO2017126700 A9 WO 2017126700A9 JP 2017002036 W JP2017002036 W JP 2017002036W WO 2017126700 A9 WO2017126700 A9 WO 2017126700A9
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
disease
vnut
activity
pharmaceutical composition
Prior art date
Application number
PCT/JP2017/002036
Other languages
French (fr)
Japanese (ja)
Other versions
WO2017126700A1 (en
Inventor
芳則 森山
孝明 宮地
政壽 野村
弘志 表
百合 加藤
啓太 辰島
昌平 坂本
Original Assignee
芳則 森山
孝明 宮地
政壽 野村
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 芳則 森山, 孝明 宮地, 政壽 野村 filed Critical 芳則 森山
Publication of WO2017126700A1 publication Critical patent/WO2017126700A1/en
Publication of WO2017126700A9 publication Critical patent/WO2017126700A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are a pharmaceutical composition containing a VNUT inhibitor and a method using a VNUT inhibitor, each of which can be employed for treating or preventing a disease or condition selected from the group consisting of non-alcoholic steatohepatitis (NASH), an inflammatory disease, pain, type-2 diabetes, dyslipidemia, an allergic disease, chronic obstructive pulmonary disease, psoriasis, a chronic pulmonary disease, asthma, atherosclerosis, cancer, an ophthalmic disease, lower urinary tract dysfunction and a thrombotic disorder. The dose of the VNUT inhibitor in the pharmaceutical composition is, for example, 0.001 to 10 mg per kg body weight of a patient.
PCT/JP2017/002036 2016-01-20 2017-01-20 Inhibitor of activity of vesicular nucleotide transporter WO2017126700A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2016009188 2016-01-20
JP2016-009188 2016-01-20
JP2016-071378 2016-03-31
JP2016071378 2016-03-31

Publications (2)

Publication Number Publication Date
WO2017126700A1 WO2017126700A1 (en) 2017-07-27
WO2017126700A9 true WO2017126700A9 (en) 2018-07-19

Family

ID=59362443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/002036 WO2017126700A1 (en) 2016-01-20 2017-01-20 Inhibitor of activity of vesicular nucleotide transporter

Country Status (1)

Country Link
WO (1) WO2017126700A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111139294A (en) * 2020-01-06 2020-05-12 中国药科大学 Application of FDPS (fully drawn protein) in preparation of drug for treating non-alcoholic steatohepatitis
CN112494472B (en) * 2021-02-04 2021-07-20 清华大学 Use of 3-hydroxybutyric acid and derivatives thereof for the treatment or prevention of immune system mediated diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
JP2001131073A (en) * 1999-11-09 2001-05-15 Sumitomo Pharmaceut Co Ltd Ache-treating agent
JP2007169176A (en) * 2005-12-20 2007-07-05 Sogo Ikagaku Kenkyusho:Kk Cytokine morbid state treatment pharmaceutical preparation
EP2159281B1 (en) * 2007-03-30 2012-09-26 National University Corporation Okayama University Novel slc17-type transporter protein in mammal and use thereof
WO2009116546A1 (en) * 2008-03-18 2009-09-24 国立大学法人 岡山大学 Excitatory chemical mediator and method for screening thereof
JP5888668B2 (en) * 2011-08-31 2016-03-22 国立大学法人広島大学 Method for producing human hepatocyte chimeric model animal with hepatitis B

Also Published As

Publication number Publication date
WO2017126700A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
EP3069720A8 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
HK1082946A1 (en) Hydroxy tetrahydro-naphthalenyurea derivatives
WO2010021680A3 (en) Inhibitors of beta-secretase
NO20076561L (en) Imidazoquinolines as Lipid Kinase Inhibitors
MX2022012716A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders.
CR10419A (en) Pyrazolo [3,4-D] -Pyrimidine derivatives useful for treating respiratory disorders
PH12019500131A1 (en) Substituted diazahetero-bicyclic compounds and their use
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
MX2009004908A (en) Chemical compounds.
JP2009506054A5 (en)
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2007071958A3 (en) Combination of zd6474 and pemetrexed
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
MD4369B1 (en) Use of glycopyrrolate for treating tachycardia, unit dose, delivery device, method of treatment and prophylaxis of tachycardia
BRPI0921692A2 (en) carbamate compound or the salt thereof
AU2003294748A1 (en) Tetrahydro-naphthalene derivatives
WO2017126700A9 (en) Inhibitor of activity of vesicular nucleotide transporter
RU2016132762A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A 15-HEPC AND METHODS FOR TREATING ASTHMA AND LUNG DISEASES WITH THEIR APPLICATION
WO2005120148A3 (en) Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17741577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17741577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: JP